AKT2 and ovarian carcinoma: Frequent amplification of AKT2 was identified in different ovarian cancer cohorts, for example in 18.2% of patients with HGSOC[57] and 10% of patients with advanced ovarian cancer (cohort comprised of 89% HGSOC)[58].